IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301)
NCT 06112314 Brief Summary This is a phase 3, randomized, controlled study…
Read more arrow_forwardNCT 06112314 Brief Summary This is a phase 3, randomized, controlled study…
Read more arrow_forwardNCT 03486873 Brief Summary The purpose of this study is to…
Read more arrow_forwardNCT 02645149 Brief Summary This is a patient oriented translational research project…
Read more arrow_forwardNCT 05735080 Brief Summary Incyclix Bio (Incyclix) is developing INX-315 as an…
Read more arrow_forwardNCT 06536257 Brief Summary This is a non-interventional study to prospectively test…
Read more arrow_forwardNCT 06092580 Brief Summary The aims of this clinical trial are (1)…
Read more arrow_forwardNCT 03212404 Brief Summary CK-301 (cosibelimab) is a fully human monoclonal antibody…
Read more arrow_forwardNCT 04106492 Brief Summary The purpose of this study is to evaluate…
Read more arrow_forwardNCT 06697301 Brief Summary The study is for patients with advanced melanoma…
Read more arrow_forwardNCT 05544552 Brief Summary The purpose of this study is to…
Read more arrow_forward